PCSK9 inhibition for primary prevention of ischaemic heart disease in heterozygous familial hypercholesterolaemia
Referencias
Additional references
Abifadel M, Varret M, Rabès J‐P, Allard D, Ouguerram K, Devillers M, et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nature Genetics 2003;34(2):154‐6.
American Diabetes Association. (2) Classification and diagnosis of diabetes. Diabetes Care 2015;38 Suppl:S8‐S16.
Besseling J, Kindt I, Hof M, Kastelein JJ, Hutten BA, Hovingh GK. Severe heterozygous familial hypercholesterolemia and risk for cardiovascular disease: a study of a cohort of 14,000 mutation carriers. Atherosclerosis 2014;233(1):219‐23.
Catapano AL, Graham I, De Backer G, Wiklund O, Chapman MJ, Drexel H, et al. 2016 ESC/EAS guidelines for the management of dyslipidaemias: The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) developed with the special contribution of the European Assocciation for Cardiovascular Prevention & Rehabilitation (EACPR). Atherosclerosis 2016;253:281‐344.
Cohen JC, Boerwinkle E, Mosley TH, Hobbs HH. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. New England Journal of Medicine 2006;354(12):1264‐72.
European Medicines Agency. Assessment report alirocumab. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_‐_Public_assessment_report/human/003882/WC500194524.pdf (accessed 24 May 2017):1‐134.
European Medicines Agency. Assessment report evolocumab. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_‐_Public_assessment_report/human/003766/WC500191400.pdf (accessed 24 May 2017):1‐122.
Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration 2011. Available from handbook.cochrane.org.
Higgins JPT, Deeks JJ, editor(s). Chapter 7: Selecting studies and collecting data. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
Higgins JPT, Altman DG, Sterne JAC, editor(s) on behalf of the Cochrane Statistical Methods Group and the Cochrane Bias Methods Group. Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
Julian PT Higgins, Jonathan J Deeks, Douglas G Altman. editor(s) on behalf of the Cochrane Statistical Methods Group. Chapter 13: Special topics in statistics. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
Horton JD, Shah NA, Warrington JA, Anderson NN, Park SW, Brown MS, et al. Combined analysis of oligonucleotide microarray data from transgenic and knockout mice identifies direct SREBP target genes. Proceedings of the National Academy of Sciences of the United States of America 2003;100(21):12027–32.
Khera AV, Won HH, Peloso GM, Lawson KS, Bartz TM, Deng X, et al. Diagnostic yield and clinical Utility of sequencing familial hypercholesterolemia genes in patients With severe hypercholesterolemia. Journal of the American College of Cardiology 2016;67(22):2578‐89.
Lagace TA, Curtis DE, Garuti R, McNutt MC, Park SW, Prather HB, et al. Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice. Journal of Clinical Investigtion 2006;116(11):2995‐3005.
Maxwell K, Fisher EA, Breslow JL. Overexpression of PCSK9 accelerates the degradation of the LDLR in a post‐endoplasmic reticulum compartment. Proceedings of the National Academy of Sciences of the United States of America 2005;102(6):2069‐74.
Mullard A. Nine paths to PCSK9 inhibition. Nature Reviews. Drug Discovery 2017;16(5):299‐301.
Liv Mundal, Sarancic M, Ose L, Iversen PO, Borgan JK, Veierød MB, et al. Mortality among patients with familial hypercholesterolemia: A registry‐based study in Norway, 1992–2010. Journal of the American Heart Association 2014;3(6):e001236.
Natarajan P, Kathiresan S. PCSK9 Inhibitors. Cell 2016;165(5):1037.
Navarese EP, Kolodziejczak M, Schulze V, Gurbel PA, Tantry U, Lin Y, et al. Effects of proprotein convertase subtilisin/kexin type 9 antibodies in adults with hypercholesterolemia: a systematic review and meta‐analysis. Annals of Internal Medicine 2015;163(1):40‐51.
Nordestgaard BG, Chapman MJ, Humphries SE, Ginsberg HN, Masana L, Descamps OS, et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. European Heart Journal 2013;34(45):3478‐90a.
Parker BA, Capizzi JA, Grimaldi AS, Clarkson PM, Cole SM, Keadle J, et al. Effect of statins on skeletal muscle function. Circulation 2013;127(1):96‐103.
Rader DJ, Cohen J, Hobbs HH. Monogenic hypercholesterolemia: new insights in pathogenesis and treatment. Journal of Clinical Investigation 2003;111(12):1795–803.
Rashid S, Curtis DE, Garuti R, Anderson NN, Bashmakov Y, Ho YK, et al. Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9. Proceedings of the National Academy of Sciences of the United States of America 2005;102(15):5374‐9.
The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
Ridker PM, Revkin J, Amarenco P, Brunell R, Curto M, Civeira F, et al. Cardiovascular efficacy and safety of bococizumab in high‐risk patients. New England Journal of Medicine 2017;376(16):1527‐39.
Ryan A, Byrne CD. Importance of early recognition of heterozygous familial hypercholesterolaemia. Current Opinion in Lipidology 2015;2(4):298‐03.
Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. New England Journal of Medicine 2017;376(18):1713‐22.
Schmidt AF, Pearce LS, Wilkins JT, Overington JP, Hingorani AD, Casas JP. PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease. Cochrane Database of Systematic Reviews 2017, Issue 4. [DOI: 10.1002/14651858.CD011748.pub2]
Slack J. Risks of ischaemic heart‐disease in familial hyperlipoproteinaemic states. Lancet 1969;2(7635):1380‐2.
Stone NJ, Levy RI, Fredrickson DS, Verter J. Coronary artery disease in 116 kindred with familial type II hyperlipoproteinemia. Circulation 1974;49(3):476‐88.
Taylor F, Huffman MD, Macedo AF, Moore THM, Burke M, Davey Smith G, et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database of Systematic Reviews 2013, Issue 1. [DOI: 10.1002/14651858.CD004816.pub5]
Thompson PD, Panza G, Zaleski A, Taylor B. Statin‐associated side effects. Journal of the American College of Cardiology 2016;67(20):2395‐410.
Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD, et al. Third universal definition of myocardial infarction. Journal of the American College of Cardiol 2012;60(16):1581‐98.
Versmissen J, Oosterveer DM, Yazdanpanah M, Defesche JC, Basart DC, Liem AH, et al. Efficacy of statins in familial hypercholesterolaemia: a long term cohort study. BMJ 2008;337:a2423.
Wong B, Kruse G, Kutikova L, Ray KK, Mata P, Bruckert E. Cardiovascular disease risk associated with familial hypercholesterolemia: a systematic review of the literature. Clinical Therapeutics 2016;38(7):1696‐709.
Zhang H, Plutzky J, Skentzos S, Morrison F, Mar P, Shubina M, et al. Discontinuation of statins in routine care settings: a cohort study. Annals of Internal Medicine 2013;158(7):526‐34.
Zhang XL, Zhu QQ, Zhu L, Chen JZ, Chen QH, Li GN, et al. Safety and efficacy of anti‐PCSK9 antibodies: a meta‐analysis of 25 randomized, controlled trials. BMC Medicine 2015;13:123.
